The third‐generation ABL1 kinase inhibitor olverembatinib was licensed in China for TKI‐resistant CML‐CP or accelerated‐phase CML harboring the T315I mutation.67 The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.